 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Journal: Drugs for age-related macular degeneration. (Pubmed Central) - Jan 12, 2025
No abstract available
- | Pavblu (aflibercept-ayyh) / Amgen, Eylea (aflibercept intravitreal) / Regeneron
Journal: Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product. (Pubmed Central) - Nov 6, 2024
No abstract available This integrated assessment of results from the in vitro pharmacology assessment and in vivo PK and TK/toxicology profiles formed the nonclinical portion of the totality of evidence demonstrating ABP
- | ABP 938 (aflibercept biosimilar) / Amgen
Journal: Analytical and Functional Similarity of Aflibercept Biosimilar ABP (Pubmed Central) - Mar 20, 2024
This integrated assessment of results from the in vitro pharmacology assessment and in vivo PK and TK/toxicology profiles formed the nonclinical portion of the totality of evidence demonstrating ABP ABP
- || Pavblu (aflibercept biosimilar) / Amgen
Trial completion: A Study to Evaluate ABP 938 and Aflibercept (Eylea (clinicaltrials.gov) - Mar 30, 2023
P3, N=49, Completed, Sponsor: Amgen
ABP Active, not recruiting --> Completed
- || Pavblu (aflibercept biosimilar) / Amgen
Enrollment closed: A Study to Evaluate ABP 938 and Aflibercept (Eylea (clinicaltrials.gov) - Mar 15, 2023
P3, N=48, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Pavblu (aflibercept biosimilar) / Amgen
Enrollment open: A Study to Evaluate ABP 938 and Aflibercept (Eylea (clinicaltrials.gov) - Feb 14, 2023
P3, N=48, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Pavblu (aflibercept biosimilar) / Amgen
Trial completion: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Feb 1, 2023
P3, N=579, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Pavblu (aflibercept biosimilar) / Amgen
New P3 trial: A Study to Evaluate ABP 938 and Aflibercept (Eylea (clinicaltrials.gov) - Jan 30, 2023
P3, N=48, Not yet recruiting, Sponsor: Amgen
- ||||| Pavblu (aflibercept biosimilar) / Amgen
Enrollment closed: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Feb 2, 2022
P3, N=579, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Pavblu (aflibercept biosimilar) / Amgen
Trial completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Aug 19, 2021
P3, N=566, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial completion date: Jun 2022 --> Dec 2022
- |||| Pavblu (aflibercept biosimilar) / Amgen
Trial primary completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Aug 18, 2021
P3, N=566, Recruiting, Sponsor: Amgen
Trial completion date: Jun 2022 --> Dec 2022 Trial primary completion date: Jan 2022 --> Jun 2022
- ||| Pavblu (aflibercept biosimilar) / Amgen
Trial completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Jun 18, 2021
P3, N=566, Recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2022 --> Jun 2022 Trial completion date: Dec 2022 --> Aug 2022
- |||| Pavblu (aflibercept biosimilar) / Amgen
Trial completion date, Trial primary completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Mar 18, 2021
P3, N=566, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2022 --> Aug 2022 Trial completion date: Jul 2023 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Feb 2022
- ||| Pavblu (aflibercept biosimilar) / Amgen
Trial completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Oct 8, 2020
P3, N=566, Recruiting, Sponsor: Amgen
Trial completion date: Jul 2023 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Feb 2022 Trial completion date: Jul 2022 --> Jul 2023
- |||||| Pavblu (aflibercept biosimilar) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Jun 28, 2020
P3, N=566, Recruiting, Sponsor: Amgen
Trial completion date: Jul 2022 --> Jul 2023 Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: May 2021 --> Sep 2021
- ||||| Pavblu (aflibercept biosimilar) / Amgen
Trial initiation date: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Mar 24, 2020
P3, N=566, Not yet recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting | Trial completion date: Mar 2022 --> Jul 2022 | Trial primary completion date: May 2021 --> Sep 2021 Initiation date: Mar 2020 --> Jul 2020
- |||||||||| Pavblu (aflibercept biosimilar) / Amgen
New P3 trial: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea (clinicaltrials.gov) - Feb 16, 2020
P3, N=566, Not yet recruiting, Sponsor: Amgen